The best way to take talquetamab (talquetamab-tgvs) and improve its effects

Talquetamab is administered by subcutaneous injection, which needs to be completed by medical personnel in the hospital. Multiple myeloma patients cannot do it by themselves. The drug is administered in gradually increasing doses to reduce the risk of immune-related reactions. The "weekly dosing" or "bi-weekly dosing" system is usually chosen based on the clinical protocol. The purpose of different protocols is to maintain stable drug exposure while ensuring safety. Although detailed dosage ladders are provided in the label, in practice, doctors often make individual adjustments based on the patient's weight, tolerance, and previous treatment history.

In order to improve the therapeutic effect, clinical practice often emphasizes several key points. First of all, the hospital monitoring process needs to be strictly followed during the loading dose phase, because the incremental phase is the most obvious stage of immune activation. By monitoring vital signs, infection indicators, and inflammatory responses, the risk of adverse events can be effectively reduced and the treatment can be ensured to proceed smoothly. Secondly, it is very important to maintain regular dosing and avoid arbitrary delays, because the immune activity of drug antibodies needs to be maintained through a stable rhythm. Once the interval is too long, it may affect the rhythm of treatment and even reduce the continuity of immune activation.

In the long-term treatment phase, hydration, nutrition, infection management, skin and mucous membrane care, etc. are also important links to improve the efficacy. Because some patients may experience skin changes, taste changes, or mild inflammatory reactions, doctors usually give lifestyle advice in advance to help patients improve tolerance. For patients with more sensitive immune systems, doctors may also use auxiliary drugs at specific stages to reduce immune-related reactions and improve treatment continuity.

Based on overseas experience, optimization of the efficacy of Tacistumumab often relies on the three principles of "standardized increments," "stable dosing," and "strict management of adverse reactions." As long as it is used under the guidance of a doctor, most patients can maintain treatment stability over a longer period of time, thereby improving overall control.

Reference materials:https://www.talveyhcp.com/